Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Zolbetuximab in CLDN18.2-positive Gastric/GEJ Adenocarcinoma
2024-511649-21-00Phase 2Authorised
- Sponsor
- Astellas Pharma
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of zolbetuximab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (5 arms), sponsored by Astellas Pharma. Primary endpoint: Objective response rate of zolbetuximab monotherapy by independent central review. Planned start May 2024; status: authorised.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-511649-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511649-21-00.